Navigation Links
Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
Date:11/9/2011

SAN FRANCISCO (Nov. 9, 2011; 12:50 p.m.) Late breaking clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet, showed patients can be "bridged" from the time that their physicians stop their oral antiplatelet drugs until they undergo cardiac surgery. Study results demonstrated cangrelor maintained target levels of platelet inhibition known to be associated with a low risk of thrombotic events, such as stent thrombosis, vs. placebo. The BRIDGE Trial results were presented here today at the Cardiovascular Research Foundation (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) conference.

"Patients with coronary stents require drugs that block platelets that can stick to their stents and cause clots. When these patients require surgery, the oral drugs must be stopped days in advance to wear off and reduce the risk of surgical bleeding; however, this puts them at an increased risk of thrombotic events," said Eric Topol, MD, cardiologist and chief academic officer at Scripps Health and BRIDGE Trial primary investigator. "With nothing available that blocks platelets and then goes away quickly, we are between the rock of thrombosis and the hard place of surgical bleeding."

BRIDGE results showed 99 percent of cangrelor-treated patients maintained target levels of platelet inhibition for all time points measured over the bridging period compared to 19 percent of placebo patients (p<0.001). The primary safety measure demonstrated no significant excess in surgical bleeding complications (data below).

The results were presented by Dominick J. Angiolillo, MD, PhD, medical director, cardiovascular research program at the University of Florida College of Medicine Jacksonville, "BRIDGE results support the hypothesis that intravenous cangrelor may be a feasible and well tolerated management strategy in patients who require prolonged platelet P2Y12 inhibition after thienopyridine discontinuation pr
'/>"/>

Contact: Rebecca Hollins
rebecca.hollins@themedco.com
973-290-6081
The Medicines Company
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... MADISON A multi-institutional team of researchers has developed ... tract. This safe, noninvasive method for assessing the function ... could lead to better diagnosis and treatment of gut ... bacterial overgrowth, irritable bowel syndrome and inflammatory bowel disease ... serious side effects in patients with diseases such as ...
(Date:7/24/2014)... biodiversity and one of the most species richness biome ... However, current levels of diversity might be still underestimated. ... in the description of new endemic species of this ... availability of samples for DNA analysis. , Using ... morphological analysis, researchers from the University of Richmond ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2New imaging agent provides better picture of the gut 2A tiny new species of frog from Brazil with a heroic name 2
... 10 years has seen a huge increase in the popularity ... kept in our homes are monkeys, tarantulas, iguanas, salamanders, snakes, ... around the world develop their conservation and captive breeding programmes ... of exotic animals. To help develop that ...
... have argued that environmental regulations can negatively impact ... by George Mason University researcher Nicole Darnall shows ... not only offset the costs of regulations, but ... which looked at more than 2,600 manufacturing facilities ...
... give birth to offspring who become even heavier, resulting ... of Medicine researchers in Houston who found that chemical ... phenomenon called epigenetics -- could affect successive generations of ... United States and it,s increasingly recognized as a worldwide ...
Cached Biology News:The exotic side of veterinary science 2The exotic side of veterinary science 3Corporations can profit from being environmentally friendly 2The epigenetics of increasing weight through the generations 2
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The first ... Dose Escalation in First in Human Studies” will cover ... better go/no-go decisions. , With increasing R&D costs and ... companies need to maximize the knowledge collected in early ... and improve success in late stage development. , Next, ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... PARIS, Sept. 7, 2011 Cellectis (Alternext: ... announced that its nuclease production capacity has ... costs. Industrialization of the nuclease manufacturing gives ... commercial subsidiary of Cellectis, the potential to ...
... and OXFORD, England, Sept. 7, 2011 CMC Biologics ... entered into a non-exclusive license agreement providing OBT with ... financial terms of which have not been disclosed, covers ... by OBT. CMC Biologics, CHEF1 cell line development platform ...
... Inc. (Nasdaq: RDEA ) announced today that it ... and Drug Administration (FDA) and successfully reached agreement on the ... plan: the overall size and design of the planned Phase ... proposed for NDA filing, manufacturing plans for both drug substance ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 2CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 3CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 2Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 3Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 4Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad 5
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: